NIH Grants $1.86 million to University of Buffalo Drug Development Programme
The National Institutes of Health (NIH) has recently awarded several grants totalling $1.86 million to the University at Buffalo?s HIV Clinical Pharmacology Research Programme. The grants are to be used to fund new initiatives in hepatitis C (HCV) drug development, nanomedicine research for tuberculosis (TB), and for the study of pharmacogenomics of neurocognitive disorders for people with HIV and AIDS.
The National Institutes of Health (NIH) has recently awarded several grants totalling $1.86 million to the University at Buffalo’s HIV Clinical Pharmacology Research Programme. The grants are to be used to fund new initiatives in hepatitis C (HCV) drug development, nanomedicine research for tuberculosis (TB), and for the study of pharmacogenomics of neurocognitive disorders for people with HIV and AIDS.
Gene D. Morse, professor of pharmacy practice and associate director of UB’s New York State Center of Excellence in Bioinformatics and Life Sciences (CoE), said: “The awards provide additional funding for the UB programme while also expanding our HIV pharmacology research to include drug development for hepatitis C and tuberculosis.”
Morse currently directs the AIDS Clinical Trials Group (ACTG) Clinical Pharmacology Core — a network of laboratories that includes pharmacology specialty laboratories (PSL) in the USA, Thailand, and Africa. The University of Buffalo pharmacology specialty laboratory investigates the development of new drugs, focusing on bioanalysis. The group currently develops and validates drug assays using innovative applications of liquid chromatography (LC) and mass spectrometry (MS).
For more information visit www.buffalo.edu/news/releases/2013/10/054.html
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.
